$11.94
0.25% day before yesterday
Nasdaq, Nov 28, 07:00 pm CET
ISIN
US23725P1003
Symbol
DRIO

DarioHealth Corp. Stock price

$11.94
-3.39 22.11% 1M
-1.97 14.14% 6M
-3.78 24.06% YTD
-2.46 17.11% 1Y
-85.66 87.77% 3Y
-239.26 95.25% 5Y
-2,644.86 99.55% 10Y
-107,268.06 99.99% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.03 0.25%
ISIN
US23725P1003
Symbol
DRIO

Key metrics

Basic
Market capitalization
$80.8m
Enterprise Value
$89.1m
Net debt
$8.3m
Cash
$22.2m
Shares outstanding
2.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.0 | 3.3
EV/Sales
3.3 | 3.7
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
60.6%
Return on Equity
-56.9%
ROCE
-42.9%
ROIC
-55.2%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$27.2m | $24.4m
EBITDA
$-36.0m | $-22.3m
EBIT
$-42.3m | $-34.5m
Net Income
$-42.4m | $-61.6m
Free Cash Flow
$-26.9m
Growth (TTM | estimate)
Revenue
41.8% | -9.7%
EBITDA
37.2% | 55.0%
EBIT
32.8% | 39.4%
Net Income
8.8% | -50.3%
Free Cash Flow
34.2%
Margin (TTM | estimate)
Gross
55.0%
EBITDA
-132.5% | -91.2%
EBIT
-155.8%
Net
-156.3% | -252.3%
Free Cash Flow
-99.2%
More
EPS
$-17.1
FCF per Share
$-11.9
Short interest
2.7%
Employees
199
Rev per Employee
$140.0k
Show more

Is DarioHealth Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

DarioHealth Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a DarioHealth Corp. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a DarioHealth Corp. forecast:

Buy
80%
Hold
20%

Financial data from DarioHealth Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
27 27
42% 42%
100%
- Direct Costs 12 12
8% 8%
45%
15 15
152% 152%
55%
- Selling and Administrative Expenses 39 39
15% 15%
142%
- Research and Development Expense 19 19
20% 20%
68%
-36 -36
37% 37%
-132%
- Depreciation and Amortization 6.32 6.32
10% 10%
23%
EBIT (Operating Income) EBIT -42 -42
33% 33%
-156%
Net Profit -42 -42
9% 9%
-156%

In millions USD.

Don't miss a Thing! We will send you all news about DarioHealth Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DarioHealth Corp. Stock News

Neutral
PRNewsWire
5 days ago
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges More fr...
Neutral
Seeking Alpha
16 days ago
DarioHealth Corp. ( DRIO ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants Zoe Harrison Erez Raphael - CEO & Director Steven Nelson - President & Chief Commercial Officer Chen Franco-Yehuda - CFO, Treasurer & Secretary Conference Call Participants Lucas Romanski - TD Cowen, Research Division Theodore O'Neill - Litchfield Hills Research, LLC Presentation Operator Good mo...
Neutral
PRNewsWire
16 days ago
Third quarter 2025 revenue was $5.0 million, compared to $7.4 million in the third quarter of 2024, and $5.4 million in the second quarter of 2025 Targeting $12.4 million in new business, reflecting both committed annual recurring revenue ("CARR") and late-stage opportunities nearing completion; 2026 pipeline expanded to $69 million Exceeded 2025 goal of 40 new signed accounts for 2026 revenue,...
More DarioHealth Corp. News

Company Profile

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in Caesarea, Israel.

Head office United States
CEO Erez Raphael
Employees 199
Founded 2011
Website shop.mydario.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today